The floor of the Geek+ factory in Hefei moves in a way that looks almost choreographed. Squat silver robots glide beneath racking, lift entire shelves, and carry them across the warehouse to a waiting picker, a process repeated thousands of times a day before the machines are boxed up and shipped abroad. Some wind up in the warehouses of Tesco, Asda, and Next. The largest deployment partner in Britain, MotionTech, has deployed a fleet of more than 2,000 robots at ten different locations. Britain has become Geek's biggest European market, and the reason is straightforward: retailers are short of labour and long on demand for faster, cheaper fulfilment.

That same calculation, workforce shortage colliding with productivity pressure, describes the NHS rather precisely. The service is running with persistent vacancy gaps across nursing, pharmacy and diagnostics, and it operates under an explicit mandate from the centre to raise output without proportionate increases in headcount. Automation has already found its way in quietly. Robotic dispensers at Queen's Hospital in Romford now retrieve and route medication in seconds, and Torbay and South Devon's inpatient pharmacy recently replaced an eighteen-year-old system with a new robot supplied by Becton Dickinson. NHS Supply Chain runs a standing framework for ward automation, unit dose robots and dispensing carts. None of this is exotic. It is the health service doing, in a modest and largely unremarked way, what British retail has been doing at far greater scale.

What changes the picture is what happened in Washington in late July. The Federal Communications Commission banned imports of new foreign-made humanoid and quadruped robots, along with power inverters, citing supply chain vulnerability and the risk that internet-connected devices could allow data collection or disruption of critical infrastructure by a foreign power. The ban is narrower than headlines suggested, it covers only new models not yet authorised for sale, exempts the federal government's own purchasing, and does not touch the wheeled warehouse robots that Geek+ ships to British retailers. However, the course of travel is clear. Washington has decided that robotics built by companies with reported ties to the Chinese state constitutes the kind of infrastructure risk that justifies market exclusion, and China supplies something like eighty five per cent of the world's humanoid robots.

The NHS has not yet had to answer this question in relation to robotics, largely because its current fleet of dispensing and logistics machines runs through Western suppliers. But the underlying supply chain is not static. Geek+ and rivals such as AgiBot are explicitly developing humanoid systems for picking and packing tasks that sit only a short conceptual step from hospital logistics, sample transport and ward supply. NHS Supply Chain has spent the past year tightening its cyber security expectations of suppliers, rolling out a Cyber Improvement Programme and requiring Cyber Essentials Plus certification for anyone touching patient data or critical services. That machinery exists because the health service has already been burned once by dependency anxiety, in the long-running scrutiny of the Federated Data Platform and its reliance on Palantir. The instinct to ask who controls the infrastructure sitting inside a hospital is not new to NHS governance.

What is missing is a forward-looking version of that instinct applied specifically to robotics, before procurement decisions are made rather than after. Washington has effectively pre-empted a category of purchase on national security grounds while the technology is still nascent in Britain. NHS leaders and the Department of Health and Social Care would do well to treat that as an early warning rather than a foreign curiosity, and to ask now which parts of an increasingly automated health service they are comfortable building on hardware whose governance sits, ultimately, outside UK jurisdiction.